Aim To evaluate the changes of plasma hs-CRP before and after percutaneous coronary intervention (PCI) and its relationship with major adverse cardiovascular events (MACE). Methods We selected 84 coronary heart disease (CHD) patients who were implanted DES. The hs-CRP level was measured before, 1 day and 30 days after the procedure. Telephone calls were made to make sure if the patients had suffered MACE including repeated angina pectoris, non-lethal myocardial infarction, in stent restenosis, repeated revascularization, cardiac death in the following year after the procedure. Results The hs-CRP decreased significantly at 30 days after PCI compared with baseline (2.80±4.66 mg/L vs. 7.52±17.90 mg/L, P＜0.001) and the level at one day after procedure (2.80±4.66 mg/L vs. 10.00±24.81 mg/L, P＜0.001). The level of hs-CRP in MACE group before PCI was significantly higher than that in MACE-free group (10.38±19.40 mg/L vs. 6.84±17.61 mg/L, P＝0.018). Conclusions The hs-CRP level before PCI in CHD patients is associated with the incidence of MACE after the procedure. Patients with higher hs-CRP level before PCI got higher incidence of MACE. The inflammation of CHD patients subsides after PCI for 30 days. The change can be reflected by the changing concentration of hs-CRP.